1357384-85-0Relevant academic research and scientific papers
Protein kinase inhibitor and its composition and use thereof
-
Paragraph 0274-0276; 0309-0311, (2017/08/02)
The invention relates to compounds as shown in the general formula (I), pharmaceutical compositions containing the compounds, a method for treating diseases and disease symptoms related to abnormal activity of protein kinase by using the compounds, and medicinal use of the compounds.
KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF
-
Page/Page column 37; 40, (2013/06/05)
The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition.
Pyrazolopyridine inhibitors of B-RafV600E. Part 3: An increase in aqueous solubility via the disruption of crystal packing
Wenglowsky, Steve,Moreno, David,Rudolph, Joachim,Ran, Yingqing,Ahrendt, Kateri A.,Arrigo, Alisha,Colson, Ben,Gloor, Susan L.,Hastings, Gregg
scheme or table, p. 912 - 915 (2012/03/26)
A single crystal was obtained of a lead B-RafV600E inhibitor with low aqueous solubility. The X-ray crystal structure revealed hydrogen-bonded head-to-tail dimers formed by the pyrazolopyridine and sulfonamide groups of a pair of molecules. Thi
